Spago Nanomedical AB
Spago Nanomedical AB (publ), a clinical phase nanomedicine company, engages in the development of nanomedicines for cancer diagnostics and treatment primarily in Sweden. Its products include SpagoPix (SN132D), an MRI contrast agent, which is under Phase I development stage for the treatment of breast cancer, and under Phase II development stage for the treatment liver and pancreas cancer, as well… Read more
Spago Nanomedical AB (SPAGO) - Total Liabilities
Latest total liabilities as of December 2025: Skr5.94 Million SEK
Based on the latest financial reports, Spago Nanomedical AB (SPAGO) has total liabilities worth Skr5.94 Million SEK as of December 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Spago Nanomedical AB - Total Liabilities Trend (2011–2025)
This chart illustrates how Spago Nanomedical AB's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Spago Nanomedical AB Competitors by Total Liabilities
The table below lists competitors of Spago Nanomedical AB ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Kumwell Corporation Public Company Limited
BK:KUMWEL
|
Thailand | ฿279.36 Million |
|
Spectrumone publ AB
ST:SPEONE
|
Sweden | Skr40.81 Million |
|
Southern ITS International Inc
PINK:SITS
|
USA | $13.06 Million |
|
Comelf SA
RO:CMF
|
Romania | RON80.77 Million |
|
Streamplay Studio Ltd
AU:SP8
|
Australia | AU$7.18 Million |
|
Shiva Texyarn Limited
NSE:SHIVATEX
|
India | ₹-1.36 Billion |
|
Sung Gang Asset Management Ltd
TWO:6240
|
Taiwan | NT$543.57 Million |
Liability Composition Analysis (2011–2025)
This chart breaks down Spago Nanomedical AB's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 6.96 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.19 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.16 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Spago Nanomedical AB's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Spago Nanomedical AB (2011–2025)
The table below shows the annual total liabilities of Spago Nanomedical AB from 2011 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | Skr5.94 Million | -6.47% |
| 2024-12-31 | Skr6.35 Million | -45.59% |
| 2023-12-31 | Skr11.67 Million | +32.64% |
| 2022-12-31 | Skr8.80 Million | +29.14% |
| 2021-12-31 | Skr6.81 Million | +116.53% |
| 2020-12-31 | Skr3.15 Million | +8.15% |
| 2019-12-31 | Skr2.91 Million | -29.00% |
| 2018-12-31 | Skr4.10 Million | +7.50% |
| 2017-12-31 | Skr3.81 Million | -53.63% |
| 2016-12-31 | Skr8.22 Million | -11.90% |
| 2015-12-31 | Skr9.33 Million | -52.23% |
| 2014-12-31 | Skr19.53 Million | -0.81% |
| 2013-12-31 | Skr19.69 Million | +73.35% |
| 2012-12-31 | Skr11.36 Million | -8.57% |
| 2011-12-31 | Skr12.42 Million | -- |